MX2018015172A - Metodos para tratar cancer pancreatico. - Google Patents

Metodos para tratar cancer pancreatico.

Info

Publication number
MX2018015172A
MX2018015172A MX2018015172A MX2018015172A MX2018015172A MX 2018015172 A MX2018015172 A MX 2018015172A MX 2018015172 A MX2018015172 A MX 2018015172A MX 2018015172 A MX2018015172 A MX 2018015172A MX 2018015172 A MX2018015172 A MX 2018015172A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
treating pancreatic
methods
oncogenes
patients
Prior art date
Application number
MX2018015172A
Other languages
English (en)
Inventor
Bekker Petrus
Charo Israel
Miao Shichang
Schall Tom
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2018015172A publication Critical patent/MX2018015172A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente descripción describe métodos para tratar el cáncer pancreático y limitar la sobreexpresión de oncogenes, activar genes supresores de tumores o regular proteínas de señalización en pacientes que comprenden la administración de compuestos y combinaciones farmacéuticas como se describe en la presente.
MX2018015172A 2016-06-13 2017-06-13 Metodos para tratar cancer pancreatico. MX2018015172A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349217P 2016-06-13 2016-06-13
US201662382689P 2016-09-01 2016-09-01
PCT/US2017/037264 WO2017218544A1 (en) 2016-06-13 2017-06-13 Methods of treating pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2018015172A true MX2018015172A (es) 2019-07-04

Family

ID=60663739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015172A MX2018015172A (es) 2016-06-13 2017-06-13 Metodos para tratar cancer pancreatico.

Country Status (14)

Country Link
EP (1) EP3468548B1 (es)
JP (3) JP7083214B2 (es)
KR (2) KR20230047210A (es)
CN (1) CN109562086A (es)
AU (1) AU2017283491B2 (es)
BR (1) BR112018075660A2 (es)
CA (1) CA3026515A1 (es)
ES (1) ES2895749T3 (es)
IL (1) IL263508B2 (es)
MX (1) MX2018015172A (es)
RU (1) RU2768479C2 (es)
SG (2) SG11201810940XA (es)
WO (1) WO2017218544A1 (es)
ZA (1) ZA201808258B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
EP3468548B1 (en) * 2016-06-13 2021-08-04 ChemoCentryx, Inc. Methods of treating pancreatic cancer
WO2020060247A1 (ko) * 2018-09-19 2020-03-26 오토텔릭바이오 주식회사 항암용 조성물
WO2022042537A1 (zh) * 2020-08-24 2022-03-03 江苏恒瑞医药股份有限公司 TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途
WO2023040804A1 (zh) * 2021-09-14 2023-03-23 信达生物制药(苏州)有限公司 抗pd-1抗体和化疗药的药物组合及其使用方法
CN115521913B (zh) * 2022-02-22 2023-07-25 北京景达生物科技有限公司 NK细胞与CD20、CD38、Her2抗体联合应用
CN116804221B (zh) * 2023-08-23 2023-11-03 汲迈生命科技(苏州)有限公司 Lmo7表达水平在预测胰腺癌吉西他滨耐药中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52010B (en) * 2005-06-22 2012-04-30 Plexxikon Inc. DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2099454A4 (en) * 2006-11-17 2010-11-10 Abbott Lab AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
PL2175859T3 (pl) * 2007-07-12 2012-09-28 Chemocentryx Inc Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
CA2709806A1 (en) * 2008-01-22 2009-07-30 Merck Patent Gmbh Protein kinase inhibitors and use thereof
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MX2012006964A (es) * 2009-12-17 2012-07-17 Boehringer Ingelheim Int Nuevos antagonistas del receptor ccr2 y usos de los mismos.
US8916601B2 (en) * 2012-02-29 2014-12-23 Chemocentryx, Inc. Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides
US10189777B2 (en) * 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
EP3468548B1 (en) 2016-06-13 2021-08-04 ChemoCentryx, Inc. Methods of treating pancreatic cancer

Also Published As

Publication number Publication date
ES2895749T3 (es) 2022-02-22
WO2017218544A1 (en) 2017-12-21
IL263508A (en) 2019-01-31
ZA201808258B (en) 2022-04-28
JP2019518038A (ja) 2019-06-27
BR112018075660A2 (pt) 2019-04-09
RU2019100220A3 (es) 2020-12-24
KR20230047210A (ko) 2023-04-06
AU2017283491B2 (en) 2021-06-03
EP3468548A1 (en) 2019-04-17
IL263508B2 (en) 2023-06-01
AU2017283491A1 (en) 2018-12-20
CA3026515A1 (en) 2017-12-21
EP3468548B1 (en) 2021-08-04
JP2020147602A (ja) 2020-09-17
KR20190017913A (ko) 2019-02-20
JP7083214B2 (ja) 2022-06-10
JP2020147601A (ja) 2020-09-17
EP3468548A4 (en) 2020-01-22
SG11201810940XA (en) 2019-01-30
SG10202012434QA (en) 2021-01-28
RU2019100220A (ru) 2020-07-15
RU2768479C2 (ru) 2022-03-24
CN109562086A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
MX2018015172A (es) Metodos para tratar cancer pancreatico.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2022000085A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
PH12019501959A1 (en) Therapeutic rna
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
EP3795676A4 (en) APPLICATION OF B. FRAGILIS OR AKKERMANSIA MUCINIPHILA IN THE PREPARATION OF A MEDICINE INTENDED FOR PREVENTING OR TREATING A TUMOR
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2017013142A (es) Terapia combinada para tratar cáncer.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.